Use of Convalescent Plasma for COVID-19

Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak

The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe whether this will result in a significant improvement in clinical outcome in comparison to historical experience.

Inclusion Criteria:

• Documented COVID-19 infection by nasal pharyngeal sampling
• COVID-19 disease falling into one of the following groups:
• Critical disease: respiratory failure requiring mechanical ventilation, pressor support, or multiple organ dysfunction/failure
• Severe disease: tachypnea >/=30 per min, O2 sats </=93% at rest, PaO2/FiO2 index </=300mmHg
• High Risk: upper respiratory symptoms but no radiographic evidence of disease, immunocompromised, insulin-dependent diabetes, poorly controlled HIV disease, moderate to severe asthma history, severe COPD, morbid obesity (BMI >/=40, age >/=65 years
• Health Care Providers: health care providers at risk to exposure to COVID-19 infection or those with mild to non-severe disease

Exclusion Criteria:

• History of IgA deficiency
• History of anaphylatic reaction to blood product transfusion including hypersensitivity to immunoglobulin therapy